170 related articles for article (PubMed ID: 36943449)
21. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
23. Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma: A Single-Center, Retrospective Study.
Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Okada Y; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
Ann Surg Oncol; 2024 Jan; 31(1):525-534. PubMed ID: 37851194
[TBL] [Abstract][Full Text] [Related]
24. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
26. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
Nakamura T; Asano T; Okamura K; Tsuchikawa T; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Shichinohe T; Hirano S
J Gastrointest Surg; 2019 May; 23(5):990-996. PubMed ID: 30242645
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
28. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.
Ikuta S; Aihara T; Yamanaka N
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e109-e114. PubMed ID: 30632282
[TBL] [Abstract][Full Text] [Related]
29. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
30. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study.
Man Q; Pang H; Liang Y; Chang S; Wang J; Gao S
Medicine (Baltimore); 2024 Mar; 103(10):e37440. PubMed ID: 38457597
[TBL] [Abstract][Full Text] [Related]
31. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
[TBL] [Abstract][Full Text] [Related]
32. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
[TBL] [Abstract][Full Text] [Related]
33. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
34. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes.
Yu D; An G; Yao J
J Clin Lab Anal; 2021 Sep; 35(9):e23944. PubMed ID: 34418175
[TBL] [Abstract][Full Text] [Related]
35. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
36. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
37. A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.
Ikuta S; Sonoda T; Aihara T; Yamanaka N
Ann Transl Med; 2019 Sep; 7(18):461. PubMed ID: 31700897
[TBL] [Abstract][Full Text] [Related]
38. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery.
Kondo N; Uemura K; Sumiyoshi T; Okada K; Seo S; Otsuka H; Kawano R; Murakami Y; Takahashi S
Dig Surg; 2021; 38(5-6):352-360. PubMed ID: 34689146
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas.
Kanda T; Wakiya T; Ishido K; Kimura N; Fujita H; Yoshizawa T; Goto S; Tatara Y; Kijima H; Hakamada K
J Gastroenterol; 2022 Oct; 57(10):798-811. PubMed ID: 35780404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]